Correspondence on 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'

Ann Rheum Dis. 2023 Jan;82(1):e23. doi: 10.1136/annrheumdis-2020-219312. Epub 2021 Feb 4.

Authors

Akshay Parikh¹, Phani Kumar Devarasetti¹, Liza Rajasekhar²

Affiliations

¹ Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.
² Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India lizarajasekhar@gmail.com.

PMID: 33542103
DOI: 10.1136/annrheumdis-2020-219312

No abstract available

Keywords: glucocorticoids; rituximab; systemic vasculitis.

Publication types

Letter
Comment

MeSH terms

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
Glucocorticoids
Humans
Immunosuppressive Agents*
Recurrence
Remission Induction
Rituximab / therapeutic use

Substances

Rituximab
Immunosuppressive Agents
Glucocorticoids